Results 151 to 160 of about 663,256 (217)

Development and validation of an interpretable machine learning model for predicting progression-free survival after immunotherapy in patients with non-small cell lung cancer: a multicenter study. [PDF]

Front Immunol
Li Y, Xia J, He T, Hu Y, Zhou D, Zou D, Li B, Zhang M, Huang Z, Zhang M, Liu X, Wang M, Luo H, Lu F, Zhang C, Zhao X, Su S, Peng J.   +17 more
europepmc   +1 more source

Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios. [PDF]

Eur J Nucl Med Mol Imaging
Melhorn P, Kretschmer-Chott E, Mazal P, Raderer M, Kiesewetter B.   +4 more
europepmc   +1 more source

Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study

Shijun Li, Cuicui Zhang, Xinyue Wang, Jing Wang, Kai Li   +4 more
openalex   +1 more source

Heterogeneity of progression-free survival surrogacy by sex in randomized trials testing immunotherapy in non-small cell lung cancer. [PDF]

JNCI Cancer Spectr
Pagan E, Sala I, Pala L, Natali F, Merlo F, Oriecuia C, Specchia C, De Pas T, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, Cascetta P, Facella F, Tinterri B, Pino M, Canzian J, Giaccone G, Bagnardi V, Conforti F.   +20 more
europepmc   +1 more source

Treatment modalities in recurrent brain metastases: a combined institutional and individual patient data meta-analysis of post-recurrence survival and local progression-free survival. [PDF]

J Neurooncol
Basaran AE, Fahsold L, Lordick F, Nicolay NH, Güresir E, Wach J.   +5 more
europepmc   +1 more source

Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patients [PDF]

Abdou Khadir Dia, Alona Kolnohuz, Sevinj Yolchuyeva, Marion Tonneau, Fabien Lamaze, Michele Orain, Andréanne Gagné, Florence Blais, François Coulombe, Julie Malo, Wiam Belkaïd, Arielle Elkrief, Drew F. K. Williamson, Bertrand Routy, Philippe Joubert, Mathieu Laplante, Steve Bilodeau, Venkata Manem   +17 more
openalex   +1 more source

Prognostic value of LDH and α-HBDH dynamic levels for 1-year overall survival and progression-free survival in patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy. [PDF]

Front Oncol
Li W, Du G, Lu S, Zhu H, Zhao K, Yu J, Yang Y.   +6 more
europepmc   +1 more source

Figure 3 from Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study

Ruiliang Wang, Jing Xu, Chenyi Zhu, Wujianhong Liu, Chengqi Jin, Wentao Luo, Tingting Zhao, Changcheng Guo, Wei Chen, Bin Yang   +9 more
openalex   +1 more source

Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies

, 2019
Ioannis Politikos, Sean M. Devlin, Molly Maloy, Christopher Mazis, Kristine Naputo, Aishat Olaide Afuye, Andromachi Scaradavou, Richard J. O’Reilly, Scott T. Avecilla, Hugo Castro‐Malaspina, Christina Cho, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Miguel‐Angel Perales, Craig S. Sauter, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, Marcel R.M. van den Brink, James W. Young, Doris M. Ponce, Juliet N. Barker   +25 more
openalex   +1 more source

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a case report. [PDF]

Front Oncol
Ke Z, Yang H, Xing M, Bi S, Yang F.
europepmc   +1 more source